Naperville, IL -- (SBWIRE) -- 06/06/2012 -- Chelsea Therapeutics Product Pipeline Review 2012 provides data on the Chelsea Therapeutics International Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Chelsea Therapeutics International Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Chelsea Therapeutics International Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Chelsea Therapeutics International Ltd. - Brief Chelsea Therapeutics International Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Chelsea Therapeutics International Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Chelsea Therapeutics International Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Chelsea Therapeutics' pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Chelsea Therapeutics International Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Chelsea Therapeutics International Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Chelsea Therapeutics International Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Chelsea Therapeutics International Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Chelsea Therapeutics International Ltd. and identify potential opportunities in those areas.
Keyword
Current R&D Portfolio of Chelsea Therapeutics International Ltd.; Chelsea Therapeutics International Ltd. - Key Therapeutics; Chelsea Therapeutics International Ltd. - Pipeline Overview and Promising Molecules; Chelsea Therapeutics International Ltd. - News; Chelsea Therapeutics International Ltd. - Latest Updates; Chelsea Therapeutics International Ltd. - Pipeline; Chelsea Therapeutics International Ltd. - Discontinued/Dormant Projects
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/67531/chelsea-therapeutics-international-ltd-product-pipeline-review-2012.html